JP2015529676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529676A5 JP2015529676A5 JP2015531646A JP2015531646A JP2015529676A5 JP 2015529676 A5 JP2015529676 A5 JP 2015529676A5 JP 2015531646 A JP2015531646 A JP 2015531646A JP 2015531646 A JP2015531646 A JP 2015531646A JP 2015529676 A5 JP2015529676 A5 JP 2015529676A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cells expressing
- cell antigen
- antigen
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 108010001441 Phosphopeptides Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216649.2 | 2012-09-18 | ||
| GB201216649A GB201216649D0 (en) | 2012-09-18 | 2012-09-18 | Agents and methods |
| PCT/GB2013/052427 WO2014045022A2 (en) | 2012-09-18 | 2013-09-17 | Agents and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529676A JP2015529676A (ja) | 2015-10-08 |
| JP2015529676A5 true JP2015529676A5 (https=) | 2016-12-22 |
Family
ID=47144453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531646A Withdrawn JP2015529676A (ja) | 2012-09-18 | 2013-09-17 | 作用物質および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150297745A1 (https=) |
| EP (1) | EP2897642A2 (https=) |
| JP (1) | JP2015529676A (https=) |
| CN (1) | CN104812413A (https=) |
| AU (1) | AU2013319980C1 (https=) |
| CA (1) | CA2885133A1 (https=) |
| GB (1) | GB201216649D0 (https=) |
| WO (1) | WO2014045022A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| WO2016023040A1 (en) * | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| FI3377103T4 (fi) * | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
| JP2017141172A (ja) * | 2016-02-08 | 2017-08-17 | 日本全薬工業株式会社 | 抗イヌｃｄ７０モノクローナル抗体 |
| CN113603780B (zh) * | 2017-03-28 | 2022-07-01 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| WO2019222252A1 (en) * | 2018-05-15 | 2019-11-21 | Merck Patent Gmbh | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| FI3898668T3 (fi) | 2018-12-19 | 2023-11-28 | Humabs Biomed Sa | B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä |
| RS67553B1 (sr) | 2018-12-20 | 2026-01-30 | Humabs Biomed Sa | Kombinovana hbv terapija |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| JP2022542321A (ja) * | 2019-07-29 | 2022-09-30 | デヴェラ セラピューティクス インコーポレイテッド | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311895T1 (de) * | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| EP0659438A1 (en) * | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
| AU721927B2 (en) * | 1995-12-22 | 2000-07-20 | Immunomedics Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| CN103561771B (zh) * | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| WO2013139789A1 (en) * | 2012-03-19 | 2013-09-26 | Deutsches Krebsforschungszentrum | B-cell receptor complex binding proteins containing t-cell epitopes |
-
2012
- 2012-09-18 GB GB201216649A patent/GB201216649D0/en not_active Ceased
-
2013
- 2013-09-17 EP EP13782809.1A patent/EP2897642A2/en not_active Withdrawn
- 2013-09-17 AU AU2013319980A patent/AU2013319980C1/en not_active Expired - Fee Related
- 2013-09-17 WO PCT/GB2013/052427 patent/WO2014045022A2/en not_active Ceased
- 2013-09-17 CA CA 2885133 patent/CA2885133A1/en not_active Abandoned
- 2013-09-17 US US14/428,449 patent/US20150297745A1/en not_active Abandoned
- 2013-09-17 CN CN201380059696.9A patent/CN104812413A/zh active Pending
- 2013-09-17 JP JP2015531646A patent/JP2015529676A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529676A5 (https=) | ||
| Vermaelen | Vaccine strategies to improve anti-cancer cellular immune responses | |
| Liu et al. | Injectable supramolecular hydrogel for locoregional immune checkpoint blockade and enhanced cancer chemo-immunotherapy | |
| Cuzzubbo et al. | Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments | |
| Bijker et al. | Design and development of synthetic peptide vaccines: past, present and future | |
| Lichty et al. | Going viral with cancer immunotherapy | |
| Melssen et al. | Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer | |
| Wu et al. | Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation | |
| JP5539460B2 (ja) | 癌免疫治療のための組成物および方法 | |
| Sharma et al. | Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors | |
| Li et al. | TLR agonists as adjuvants for cancer vaccines | |
| JP6698541B2 (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
| Maynard et al. | Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication | |
| Srivastava et al. | SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines | |
| den Brok et al. | Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction | |
| CN106687138B (zh) | 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物 | |
| CA2840959A1 (en) | Vaccine composition | |
| JP2015533376A5 (https=) | ||
| Lopez et al. | Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection | |
| KR20250044945A (ko) | 기존의 미생물 면역을 활용한 암 치료 | |
| Qiao et al. | A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice | |
| JP2020528449A5 (https=) | ||
| Qu et al. | A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity | |
| Volckmar et al. | Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver | |
| Kamel et al. | Advancement insights in cancer vaccines: mechanisms, types, and clinical applications |